Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men

Prostate Cancer and Prostatic Diseases volume 20, pages 348–351 (2017)Cite this article

Subjects

Abstract

Background:

Analysis of systematic 12-core biopsies (SBx) has shown that African-American (AA) men tend to harbor higher risk prostate cancer (PCa) at presentation relative to other races. Multiparametric magnetic resonance imaging (mpMRI) and MRI-ultrasound fusion-guided biopsy (FBx) have been shown to diagnose more intermediate- and high-risk PCa in the general population; however, the efficacy in AA remains largely uncharacterized. We aim to evaluate the utility of FBx in an AA patient cohort.

Methods:

Men suspected of PCa underwent an mpMRI and FBx with concurrent SBx from 2007 to 2015 in this institutional review board-approved prospective cohort study. Patient demographics, imaging and fusion biopsy variables were collected. χ2, Mann–Whitney U-test and McNemar’s tests were performed to compare proportions, means and paired variables, respectively. Clinically significant PCa (CSPCa) was defined as Gleason score ⩾3+4.

Results:

Fusion biopsy demonstrated exact agreement with SBx risk categories in 64% of AA men. There was no statistically significant difference in the detection of CSPCa between FBx vs SBx (68 vs 62 cases, P=0.36). However, FBx detected 41% fewer cases of clinically insignificant PCa (CIPCa) compared with SBx (FBx 30 vs SBx 51 cases, P=0.0004). The combined FBx/SBx biopsy approach detected significantly more cases of CSPCa (FBx/SBx 80 vs SBx 62 cases, P=0.004) while detecting comparable number of cases of CIPCa (FBx/SBx 45 vs SBx 51 cases, P=0.37) compared with SBx alone. FBx/SBx also detected more CSPCa in patients with a history of prior negative SBx (FBx/SBx 28 vs 19 cases, P=0.003).

Conclusions:

FBx when used in combination with SBx detected more cases of CSPCa while not significantly increasing the diagnosis of CIPCa in AA men. Future multicenter studies will be needed to validate ultimately the clinical implications of FBx in AA patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Torre LA, Siegel RL, Ward EM, Jemal A . Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev 2015; 25: 16–27.

    Article  Google Scholar 

  2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–1092.

    Article  Google Scholar 

  3. Gronberg H . Prostate cancer epidemiology. Lancet (London, England) 2003; 361: 859–864.

    Article  Google Scholar 

  4. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. Cancer J Clin 2016; 66: 290–308.

    Article  Google Scholar 

  5. Jemal A, Center MM, DeSantis C, Ward EM . Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893–1907.

    Article  Google Scholar 

  6. Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L et al. Prostate cancer severity among low income, uninsured men. J Urol 2009; 181: 579–583;discussion 83–84.

    Article  Google Scholar 

  7. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015; 313: 390–397.

    Article  CAS  Google Scholar 

  8. Scialpi M, Piscioli I, Malaspina S, D'Andrea A . Multiparametric magnetic resonance imaging-ultrasound fusion-guided prostate biopsy: role in diagnosis and management of prostatic cancer. Urol Oncol 2014; 32: 509–510.

    Article  Google Scholar 

  9. Sonn GA, Margolis DJ, Marks LS . Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol 2014; 32: 903–911.

    Article  Google Scholar 

  10. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL et al. Prostate cancer: value of multiparametric MR imaging at 3T for detection—histopathologic correlation. Radiology 2010; 255: 89–99.

    Article  Google Scholar 

  11. Yerram NK, Volkin D, Turkbey B, Nix J, Hoang AN, Vourganti S et al. Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int 2012; 110: E783–E788.

    Article  Google Scholar 

  12. Radiology ACo. Prostate Imaging Reporting and Data System (PIRADS). Available at: http://www.acr.org/Quality-Safety/Resources/PIRADS. Last accessed April 2016.

  13. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W . Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183: 1792–1796.

    Article  Google Scholar 

  14. Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vila H et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev 2008; 17: 2825–2834.

    Article  Google Scholar 

  15. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL . Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009; 101: 984–992.

    Article  Google Scholar 

  16. Shin T, Smyth TB, Ukimura O, Ahmadi N, de Castro Abreu AL, Oishi M et al. Detection of prostate cancer using magnetic resonance imaging/ultrasonography image-fusion targeted biopsy in African-American men. BJU Int 2017.

  17. Muthigi A, George AK, Sidana A, Kongnyuy M, Simon R, Moreno V et al. Missing the mark: prostate cancer upgrading by systematic biopsy over magnetic resonance imaging/transrectal ultrasound fusion biopsy. J Urol 2017; 197: 327–334.

    Article  Google Scholar 

  18. Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Fascelli M et al. The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Urol Oncol 2016; 34: 254.e15–254.e21.

    Article  Google Scholar 

  19. Kongnyuy M, George AK, Rastinehad AR, Pinto PA . Magnetic resonance imaging-ultrasound fusion-guided prostate biopsy: review of technology, techniques, and outcomes. Curr Urol Rep 2016; 17: 32.

    Article  Google Scholar 

  20. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: A Consensus Statement by AUA and SAR. J Urol 2016; 196: 1613–1618.

    Article  Google Scholar 

  21. Rastinehad AR, Abboud SF, George AK, Frye T, Ho R, Chelluri R et al. Reproducibility of multiparametric MRI and fusion-guided prostate biopsy: multi-institutional external validation by a propensity score matched cohort. J Urol 2016; 195: 1737–1743.

    Article  Google Scholar 

  22. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011; 60: 291–303.

    Article  Google Scholar 

  23. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014; 15: e234–e242.

    Article  Google Scholar 

  24. Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE et al. Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology 2015; 85: 155–160.

    Article  Google Scholar 

  25. Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ . Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol 1997; 79: 615–617.

    Article  CAS  Google Scholar 

  26. Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006; 49: 820–826.

    Article  Google Scholar 

  27. Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS et al. Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol 2015; 68: 8–19.

    Article  Google Scholar 

  28. Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013; 63: 125–140.

    Article  Google Scholar 

  29. Muthigi A, Sidana A, George AK, Kongnyuy M, Maruf M, Valayil S et al. Current beliefs and practice patterns among urologists regarding prostate magnetic resonance imaging and magnetic resonance-targeted biopsy. Urol Oncol 2017; 35: 32.e1–32.e7.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge our data managers who prospectively maintain our databases.

Author information

Authors and Affiliations

  1. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    M Kongnyuy, A K George, A Muthigi, A Sidana, M Maruf & P A Pinto

  2. Department of Urology, University of Maryland Medical School, Baltimore, MD, USA

    M M Siddiqui

  3. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    B Turkbey & P L Choyke

  4. Center for Interventional Oncology, National Cancer Institute and Clinical Center, National Institutes of Health, Bethesda, MD, USA

    B J Wood

Authors
  1. M Kongnyuy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M M Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A K George
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Muthigi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Sidana
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Maruf
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Turkbey
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P L Choyke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B J Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P A Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Kongnyuy.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kongnyuy, M., Siddiqui, M., George, A. et al. Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men. Prostate Cancer Prostatic Dis 20, 348–351 (2017). https://doi.org/10.1038/pcan.2017.21

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2017.21

This article is cited by

Search

Advanced search

Quick links